Curing and Managing Late Toxicities in Testicular Cancer

August 2, 2014
Lawrence H. Einhorn, MD

Lawrence H. Einhorn, MD, distinguished professor of medicine, division of hematology/oncology, Indiana University School of Medicine, discusses curing and managing late toxicities in testicular cancer.

Clinical Pearls

Lawrence H. Einhorn, MD, distinguished professor of medicine, division of hematology/oncology, Indiana University School of Medicine, Giant of Cancer Care: Genitourinary Cancer, discusses curing and managing late toxicities in testicular cancer.

  • Drug resistance can be overcome by giving five times the dosage of cytolytic agents. This can be done safely because patients are given back their hematopoietic stem cells by peripheral blood stem-cell transplant.
  • Research is being conducted to improve the cure rate of testicular cancer.
  • Many young patients who are cured experience complications such as cardiovascular disease and peripheral neuropathy later.